Measurement Values Associated with Acute Branch Retinal Vein Occlusion at Baseline and One Month after Initial Treatment with Ranibizumab.

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion

W. Lloyd Clark
Mimi Liu
John Kitchens
Pin-wen Wang
Zdenka Haskova

January 2019

Abstract Background To identify baseline patient characteristics associated with early clinically si...

Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab

Akira Shiono (5235761)
Jiro Kogo (5235767)
Hiroki Sasaki (156350)
Ryo Yomoda (5235764)
Tatsuya Jujo (5235758)
Naoto Tokuda (5429678)
Yasushi Kitaoka (327367)
Hitoshi Takagi (65173)

June 2018

<div>PurposeTo examine the relationship between optical coherence tomography (OCT) images ...

Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion

Coban-Karatas M.
Altan-Yaycioglu R.
Ulas B.
Sizmaz S.
Canan H.
Sariturk C.

January 2016

Aim: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with bra...

Changes in ocular parameters following intravitreal ranibizumab therapy for branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Changes in ocular parameters following intravitreal ranibizumab therapy for branch retinal vein occl...

Measurements in eyes with central retinal vein occlusion at baseline and at 1 month and 6 months after initial treatment.

Koichiro Manabe (13520)
Rie Osaka (2635720)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Tomoyoshi Fujita (2635714)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

October 2017

Measurements in eyes with central retinal vein occlusion at baseline and at 1 month and 6 months ...

Association between the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy and baseline parameters in eyes with branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Association between the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy a...

Changes in total foveal thickness, visual acuity, and M-CHARTS score after initiating intravitreal ranibizumab therapy for macular edema associated with branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

(A)–(C), All included eyes (n = 32 eyes). (D)–(F), Eyes with no macular edema at 12 months (n = 23 e...

Baseline characteristics and treatment of eyes with acute branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Baseline characteristics and treatment of eyes with acute branch retinal vein occlusion.</p

Changes in the retinal thickness of ischemic and nonischemic branch retinal vein occlusion (BRVO).

Akira Shiono (5235761)
Jiro Kogo (5235767)
Hiroki Sasaki (156350)
Ryo Yomoda (5235764)
Tatsuya Jujo (5235758)
Naoto Tokuda (5429678)
Yasushi Kitaoka (327367)
Hitoshi Takagi (65173)

June 2018

(A) Changes in the retinal thickness of ischemic BRVO-affected areas and control areas at points ...

Associations between the M-CHARTS score at baseline and 12 months after initiating intravitreal ranibizumab therapy.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

The M-CHARTS score at baseline is significantly correlated with the M-CHARTS score 12 months after i...

Baseline Characteristics of Eyes with Acute Branch Retinal Vein Occlusion.

Koichiro Manabe (13520)
Akitaka Tsujikawa (353084)
Rie Osaka (2635720)
Yuki Nakano (1912582)
Tomoyoshi Fujita (2635714)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Akihito Uji (483605)
Yuki Muraoka (168112)

April 2016

Baseline Characteristics of Eyes with Acute Branch Retinal Vein Occlusion.</p

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion

Kaveh Abri Aghdam
Lukas Reznicek
Mostafa Soltan Sanjari
Carsten Framme
Anna Bajor
Annemarie Klingenstein
Marcus Kernt
Florian Seidensticker

June 2016

AIM: To evaluate the association between the size of peripheral retinal non-perfusion and the number...

Time to Clinically Significant Visual Acuity Gains after Ranibizumab Treatment for Retinal Vein Occlusion BRAVO and CRUISE Trials

Thach, Allen B.
Yau, Linda
Hoang, Carol
Tuomi, Lisa

May 2014

PurposeTo assess time to first achievement of clinically significant visual acuity (VA) gains from b...

Visual acuity outcomes in patients with retinal vein occlusion treated with ranibizumab according to baseline ischaemic status: an analysis of BRIGHTER and CRUISE

Taylor, SRJ
Tadayoni, R
Pearce, I
Warburton, J
Margaron, P
Wright, J
Lambrou, G

September 2014

Aim: To evaluate the visual acuity outcomes with ranibizumab (RBZ) according to baseline ischaemic s...

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion

Carmen Antía Rodríguez-Fernández
Ana Campo-Gesto
Aida López-López
Mónica Gayoso-Rey

January 2022

The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizuma...

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion

W. Lloyd Clark
Mimi Liu
John Kitchens
Pin-wen Wang
Zdenka Haskova

January 2019

Abstract Background To identify baseline patient characteristics associated with early clinically si...

Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab

Akira Shiono (5235761)
Jiro Kogo (5235767)
Hiroki Sasaki (156350)
Ryo Yomoda (5235764)
Tatsuya Jujo (5235758)
Naoto Tokuda (5429678)
Yasushi Kitaoka (327367)
Hitoshi Takagi (65173)

June 2018

<div>PurposeTo examine the relationship between optical coherence tomography (OCT) images ...

Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion

Coban-Karatas M.
Altan-Yaycioglu R.
Ulas B.
Sizmaz S.
Canan H.
Sariturk C.

January 2016

Aim: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with bra...

Changes in ocular parameters following intravitreal ranibizumab therapy for branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Changes in ocular parameters following intravitreal ranibizumab therapy for branch retinal vein occl...

Measurements in eyes with central retinal vein occlusion at baseline and at 1 month and 6 months after initial treatment.

Koichiro Manabe (13520)
Rie Osaka (2635720)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Tomoyoshi Fujita (2635714)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

October 2017

Measurements in eyes with central retinal vein occlusion at baseline and at 1 month and 6 months ...

Association between the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy and baseline parameters in eyes with branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Association between the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy a...

Changes in total foveal thickness, visual acuity, and M-CHARTS score after initiating intravitreal ranibizumab therapy for macular edema associated with branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

(A)–(C), All included eyes (n = 32 eyes). (D)–(F), Eyes with no macular edema at 12 months (n = 23 e...

Baseline characteristics and treatment of eyes with acute branch retinal vein occlusion.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

Baseline characteristics and treatment of eyes with acute branch retinal vein occlusion.</p

Changes in the retinal thickness of ischemic and nonischemic branch retinal vein occlusion (BRVO).

Akira Shiono (5235761)
Jiro Kogo (5235767)
Hiroki Sasaki (156350)
Ryo Yomoda (5235764)
Tatsuya Jujo (5235758)
Naoto Tokuda (5429678)
Yasushi Kitaoka (327367)
Hitoshi Takagi (65173)

June 2018

(A) Changes in the retinal thickness of ischemic BRVO-affected areas and control areas at points ...

Associations between the M-CHARTS score at baseline and 12 months after initiating intravitreal ranibizumab therapy.

Rie Osaka (2635720)
Koichiro Manabe (13520)
Saki Manabe (5774738)
Yuki Nakano (1912582)
Yukari Takasago (4524820)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Yuki Muraoka (168112)
Akitaka Tsujikawa (353084)

September 2018

The M-CHARTS score at baseline is significantly correlated with the M-CHARTS score 12 months after i...

Baseline Characteristics of Eyes with Acute Branch Retinal Vein Occlusion.

Koichiro Manabe (13520)
Akitaka Tsujikawa (353084)
Rie Osaka (2635720)
Yuki Nakano (1912582)
Tomoyoshi Fujita (2635714)
Chieko Shiragami (2635711)
Kazuyuki Hirooka (2635717)
Akihito Uji (483605)
Yuki Muraoka (168112)

April 2016

Baseline Characteristics of Eyes with Acute Branch Retinal Vein Occlusion.</p

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion

Kaveh Abri Aghdam
Lukas Reznicek
Mostafa Soltan Sanjari
Carsten Framme
Anna Bajor
Annemarie Klingenstein
Marcus Kernt
Florian Seidensticker

June 2016

AIM: To evaluate the association between the size of peripheral retinal non-perfusion and the number...

Time to Clinically Significant Visual Acuity Gains after Ranibizumab Treatment for Retinal Vein Occlusion BRAVO and CRUISE Trials

Thach, Allen B.
Yau, Linda
Hoang, Carol
Tuomi, Lisa

May 2014

PurposeTo assess time to first achievement of clinically significant visual acuity (VA) gains from b...

Visual acuity outcomes in patients with retinal vein occlusion treated with ranibizumab according to baseline ischaemic status: an analysis of BRIGHTER and CRUISE

Taylor, SRJ
Tadayoni, R
Pearce, I
Warburton, J
Margaron, P
Wright, J
Lambrou, G

September 2014

Aim: To evaluate the visual acuity outcomes with ranibizumab (RBZ) according to baseline ischaemic s...

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion

Carmen Antía Rodríguez-Fernández
Ana Campo-Gesto
Aida López-López
Mónica Gayoso-Rey

January 2022

The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizuma...

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion

W. Lloyd Clark
Mimi Liu
John Kitchens
Pin-wen Wang
Zdenka Haskova

January 2019

Abstract Background To identify baseline patient characteristics associated with early clinically si...

Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab

Akira Shiono (5235761)
Jiro Kogo (5235767)
Hiroki Sasaki (156350)
Ryo Yomoda (5235764)
Tatsuya Jujo (5235758)
Naoto Tokuda (5429678)
Yasushi Kitaoka (327367)
Hitoshi Takagi (65173)

June 2018

<div>PurposeTo examine the relationship between optical coherence tomography (OCT) images ...

Choroidal thickness measurements with optical coherence tomography in branch retinal vein occlusion

Coban-Karatas M.
Altan-Yaycioglu R.
Ulas B.
Sizmaz S.
Canan H.
Sariturk C.

January 2016

Aim: To evaluate central macular thickness (CMT) and mean choroidal thickness (MCT) in eyes with bra...

Measurement Values Associated with Acute Branch Retinal Vein Occlusion at Baseline and One Month after Initial Treatment with Ranibizumab.

Abstract

Extracted data

Measurement Values Associated with Acute Branch Retinal Vein Occlusion at Baseline and One Month after Initial Treatment with Ranibizumab.

Abstract

Extracted data

Related items

Related items